Challenges in the development of drugs for the treatment of tuberculosis

Brazilian Journal of Infectious Diseases

Volumn 17, Issue 1, 2013, Pages 74-81

  Shehzad, Adeeb ^a   Rehman, Gauhar ^a   Ul Islam, Mazhar ^a   Khattak, Waleed Ahmad ^a   Lee, Young Sup ^a  

^a Kyungpook National University   (South Korea)

Author keywords

Antibiotics; Drug resistance; Pathogen; Tuberculosis

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; ADENOSINE TRIPHOSPHATASE INHIBITOR; AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOSALICYLIC ACID; ANTIRETROVIRUS AGENT; AZD 5847; BEDAQUILINE; BTZ 043; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; ISONIAZID; KANAMYCIN; LINEZOLID; MOXIFLOXACIN; POSIZOLID; PROTEIN SYNTHESIS INHIBITOR; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; RITONAVIR; STREPTOMYCIN; SUTEZOLID; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

AMEBIASIS; ANEMIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BACTERIAL CLEARANCE; BACTERIAL SURVIVAL; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CHROMOSOME MUTATION; CLINICAL STUDY; COHORT ANALYSIS; DISEASE ACTIVITY; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG SUBSTITUTION; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; DYSGLYCEMIA; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE LOCUS; GENETIC RESISTANCE; HOSPITAL ACQUIRED PNEUMONIA; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NEPHROTOXICITY; NONHUMAN; OPTIC NERVE DISEASE; OTOTOXICITY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTPRIMARY TUBERCULOSIS; REVIEW; SHORT COURSE THERAPY; SKIN INFECTION; SOFT TISSUE INFECTION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TRICHOMONIASIS; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 84873127352     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/j.bjid.2012.10.009     Document Type: Short Survey

References (78)

1. Lönnroth K., Jaramillo E., Williams B.G., et al. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med 2009, 68:2240-2246.
2. Global tuberculosis control: a short update to the 2009 report. Geneva, World Health Organization 2009, WHO/HTM/TB/2009.426.
3. Zhang Y., Yew W.W. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009, 13:1320-1330.
4. Wright A., Zignol M., Van Deun A., et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 2009, 373:1861-1873.
5. Dye C., Williams B.G. The population dynamics and control of tuberculosis. Science 2010, 328:856-861.
6. Sharma S.K., Mohan A. Multidrug-resistant tuberculosis. Indian J Med Res 2004, 120:354-376.
7. Johnson R., Streicher E.M., Louw G.E., et al. Drug resistance in Mycobacterium tuberculosis. Curr Issues Mol Biol 2006, 8:97-111.
8. Slayden R.A., Barry C.E. The genetics and biochemistry of isoniazid resistance in Mycobacterium tuberculosis. Microbes Infect 2000, 2:659-669.
9. Heym B., Saint-Joanis B., Cole S.T. The molecular basis of isoniazid resistance in Mycobacterium tuberculosis. Tuber Lung Dis 1999, 79:267-271.
10. Zhang Y., Heym B., Allen B., et al. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992, 358:591-593.
11. Barry C.E., Lee R.E., Mdluli K., et al. Mycolic acids: structure, biosynthesis and physiological functions. Prog Lipid Res 1998, 37:143-179.
12. Winder F. Mode of action of the antimycobacterial agents and associated aspects of the molecular biology of mycobacteria. The biology of mycobacteria 1982, vol. 1:354-438. Academic Press, New York.
13. Banerjee A., Dubnau E., Quemard A., et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994, 263:227-230.
14. Zhang Y., Telenti A. Genetics of drug resistance in Mycobacterium tuberculosis. Molecular genetics of mycobacteria 2000, 235-254. ASM Press, Washington DC. G.F. Hatful, W.R. Jacobs (Eds.).
15. Ramaswamy S., Musser J.M. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998, 79:3-29.
16. Marttila H.J., Soini H., Eerola E. A Ser315Thr substitution in KatG is predominant in genetically heterogeneous multidrug-resistant Mycobacterium tuberculosis isolates originating from the St. Petersburg area in Russia. Antimicrob Agents Chemother 1998, 42:2443-2445.
17. Rouse D.A., DeVito J.A., Li Z., et al. Site-directed mutagenesis of the katG gene of Mycobacterium tuberculosis: effects on catalase-peroxidase activities and isoniazid resistance. Mol Microbiol 1996, 22:583-592.
18. Telenti A., Imboden P., Marchesi F., et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993, 341:647-650.
19. Herrera L., Jiménez S., Valverde A., et al. Molecular analysis of rifampicin-resistant Mycobacterium tuberculosis isolated in Spain (1996-2001). Description of new mutations in the rpoB gene and review of the literature. Int J Antimicrob Agents 2003, 21:403-408.
20. Zhang Y., Wade M.M., Scorpio A., et al. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother 2003, 52:790-795.
21. Salfinger M., Crowle A.J., Reller L.B. Pyrazinamide and pyrazinoic acid activity against tubercle bacilli in cultured human macrophages and in the BACTEC system. J Infect Dis 1990, 162:201-207.
22. Zhang Y., Scorpio A., Nikaido H., et al. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Bacteriol 1999, 181:2044-2049.
23. Sheen P., Ferrer P., Gilman R.H., et al. Effect of pyrazinamidase activity on pyrazinamide resistance in Mycobacterium tuberculosis. Tuberculosis (Edinb) 2009, 89:109-113.
24. Scorpio A., Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 1996, 2:662-667.
25. Takayama K., Kilburn J.O. Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. Antimicrob Agents Chemother 1989, 33:1493-1499.
26. Telenti A., Philipp W.J., Sreevatsan S., et al. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat Med 1997, 3:567-570.
27. Lee H.Y., Myoung H.J., Bang H.E., et al. Mutations in the embB locus among Korean clinical isolates of Mycobacterium tuberculosis resistant to ethambutol. Yonsei Med J 2002, 43:59-64.
28. Ramaswamy S.V., Amin A.G., Göksel S., et al. Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000, 44:326-336.
29. Van Niekerk C., Ginsberg A. Assessment of global capacity to conduct tuberculosis drug development trials: do we have what it takes?. Int J Tuberc Lung Dis 2009, 13:1367-1372.
30. Mitnick C., Bayona J., Palacios E., et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003, 348:119-128.
31. Ma Z., Lienhardt C., McIlleron H., et al. Global tuberculosis drug development pipeline: the need and the reality. Lancet 2010, 375:2100-2109.
32. World Health Organization The global plan to stop TB 2011-2015: transforming the fight towards elimination of tuberculosis 2010, World Health Organization.
33. Niemi M., Backman J.T., Fromm M.F., et al. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003, 42:819-850.
34. L'homme R.F., Nijland H.M., Gras L., et al. Clinical experience with the combined use of lopinavir/ritonavir and rifampicin. AIDS 2009, 23:863-865.
35. Khachi H., O'Connell R., Ladenheim D., et al. Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection. J Antimicrob Chemother 2009, 64:871-873.
36. Burman W.J., Gallicano K., Peloquin C. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. Clin Infect Dis 1999, 28:419-429.
37. Dooley K.E., Chaisson R.E. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis 2009, 9:737-746.
38. Stevenson C.R., Critchley J.A., Forouhi N.G., et al. Diabetes and the risk of tuberculosis: a neglected threat to public health?. Chronic Illn 2007, 3:228-245.
39. Lönnroth K., Williams B.G., Cegielski P., et al. A consistent log-linear relationship between tuberculosis incidence and body mass index. Int J Epidemiol 2010, 39:149-155.
40. Payne D.J., Gwynn M.N., Holmes D.J., et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007, 6:29-40.
41. Pethe K., Sequeira P.C., Agarwalla S., et al. A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nat Commun 2010, 1:57.
42. Koul A., Dendouga N., Vergauwen K., et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 2007, 3:323-324.
43. Makarov V., Manina G., Mikusova K., et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 2009, 324:801-804.
44. Williams K.N., Stover C.K., Zhu T., et al. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother 2009, 53:1314-1319.
45. Charest M.G., Lerner C.D., Brubaker J.D., et al. A convergent enantioselective route to structurally diverse 6-deoxytetracycline antibiotics. Science 2005, 308:395-398.
46. Andries K., Verhasselt P., Guillemont J., et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005, 307:223-227.
47. Huitric E., Verhasselt P., Andries K., Hoffner S.E. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2007, 51:4202-4204.
48. Haagsma A.C., Abdillahi-Ibrahim R., Wagner M.J., et al. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob Agents Chemother 2009, 53:1290-1292.
49. Koul A., Vranckx L., Dendouga N., et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem 2008, 283:25273-25280.
50. Ibrahim M., Andries K., Lounis N., et al. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother 2007, 51:1011-1015.
51. Lounis N., Veziris N., Chauffour A., Truffot-Pernot C., Andries K., Jarlier V. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother 2006, 50:3543-3547.
52. Keshavjee S., Farmer P.E. Tuberculosis, drug resistance, and the history of modern medicine. N Engl J Med 2012, 367:931-936.
53. Global Alliance for TB Drug Development. Evaluation of early bactericidal activity in pulmonary tuberculosis. US National Institutes of Health, ClinicalTrials.gov. [ClinicalTrials.gov identifier ]. ctgov:NCT00944021.
54. Yew W.W., Chau C.H., Wen K.H. Linezolid in the treatment of 'difficult' multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2008, 12:345-346.
55. Migliori G.B., Eker B., Richardson M.D., et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009, 34:387-393.
56. Diacon A.H., Dawson R., Hanekom M., et al. The safety, tolerability and early bactericidal activity and pharmacokinetics of PA824 in previously untreated, uncomplicated, sputum smear-positive pulmonary tuberculosis patients. Antimicrob Agents Chemother 2010, 54:3402-3407.
57. Williams K.N., Brickner S.J., Stover C.K., et al. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am J Respir Crit Care Med 2009, 180:371-376.
58. Wallis R.S., Jakubiec W.M., Kumar V., et al. Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrob Agents Chemother 2011, 55:567-574.
59. Fischbach M.A., Walsh C.T. Antibiotics for emerging pathogens. Science 2009, 325:1089-1093.
60. Van den Boogaard J., Kibiki G.S., Kisanga E.R., Boeree M.J., Aarnoutse R.E. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother 2009, 53:849-862.
61. Lienhardt C., Raviglione M., Spigelman M., et al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis 2012, 205:S241-S249.
62. Tyagi S., Nuermberger E., Yoshimatsu T., et al. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 2005, 49:2289-2293.
63. Lenaerts A.J., Gruppo V., Marietta K.S., et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 2005, 49:2294-2301.
64. Ginsberg A.M. Drugs in development for tuberculosis. Drugs 2010, 70:2201-2214.
65. Nuermberger E., Rosenthal I., Tyagi S., et al. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 2006, 50:2621-2625.
66. Nuermberger E., Tyagi S., Tasneen R., et al. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 2008, 52:1522-1524.
67. Diacon A.H., Dawson R., Hanekom M., et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother 2010, 54:3402-3407.
68. Collin F., Karkare S., Maxwell A. Exploiting bacterial DNA gyrase as a drug target: current state and perspectives. Appl Microbiol Biotechnol 2011, 92:479-497.
69. Rustomjee R., Lienhardt C., Kanyok T., et al. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc LungDis 2008, 12:128-138.
70. Rodríguez J.C., Ruiz M., López M., et al. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents 2002, 20:464-467.
71. Cynamon M., Sklaney M.R. Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis. Antimicrob Agents Chemother 2003, 47:2442-2444.
72. Johnson J.L., Hadad D.J., Boom W.H., et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006, 10:605-612.
73. Park-Wyllie L.Y., Juurlink D.N., Kopp A., et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006, 354:1352-1361.
74. Gavin J.R., Kubin R., Choudhri S., et al. Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies. Drug Saf 2004, 27:671-686.
75. Quinolone antimicrobial agents 2003, ASM Press, Washington, DC. 3rd ed. D.C. Hooper, E. Rubinstein (Eds.).
76. Weiner M., Burman W., Luo C.C., et al. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother 2007, 51:2861-2871.
77. Nijland H.M., Ruslami R., Suroto A.J., et al. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis 2007, 45:1001-1007.
78. http://whqlibdoc.who.int/hq/1997/who_tb_96.%20210_(rev.1).pdf.